[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1155647A1 - 含有 受體激動劑及糖醇的固體藥物組合物 - Google Patents

含有 受體激動劑及糖醇的固體藥物組合物

Info

Publication number
HK1155647A1
HK1155647A1 HK11109933.8A HK11109933A HK1155647A1 HK 1155647 A1 HK1155647 A1 HK 1155647A1 HK 11109933 A HK11109933 A HK 11109933A HK 1155647 A1 HK1155647 A1 HK 1155647A1
Authority
HK
Hong Kong
Prior art keywords
receptor agonist
sugar alcohol
oral composition
solid oral
solid
Prior art date
Application number
HK11109933.8A
Other languages
English (en)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1155647(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1155647A1 publication Critical patent/HK1155647A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK11109933.8A 2003-04-08 2011-09-21 含有 受體激動劑及糖醇的固體藥物組合物 HK1155647A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
HK1155647A1 true HK1155647A1 (zh) 2012-05-25

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
HK05102715A HK1071685A1 (en) 2003-04-08 2005-03-31 Pharmaceutical composition comprising an s1p receptor agonist
HK06107621.6A HK1091114A1 (en) 2003-04-08 2006-07-06 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK11109933.8A HK1155647A1 (zh) 2003-04-08 2011-09-21 含有 受體激動劑及糖醇的固體藥物組合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK05102715A HK1071685A1 (en) 2003-04-08 2005-03-31 Pharmaceutical composition comprising an s1p receptor agonist
HK06107621.6A HK1091114A1 (en) 2003-04-08 2006-07-06 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol

Country Status (42)

Country Link
US (11) US20060275357A1 (zh)
EP (5) EP1613288B1 (zh)
JP (3) JP5495467B2 (zh)
KR (3) KR101367574B1 (zh)
CN (2) CN101797241B (zh)
AR (3) AR043987A1 (zh)
AT (3) AT501681B1 (zh)
AU (1) AU2004228929B2 (zh)
BE (2) BE1015972A5 (zh)
BR (1) BRPI0409250B8 (zh)
CA (2) CA2707750A1 (zh)
CL (2) CL2004000745A1 (zh)
CY (3) CY1110260T1 (zh)
DE (4) DE602004017847D1 (zh)
DK (2) DK1613288T3 (zh)
EC (1) ECSP056090A (zh)
ES (3) ES2320767T3 (zh)
FR (2) FR2854073B1 (zh)
GB (1) GB2400318B (zh)
GR (1) GR1005052B (zh)
HK (3) HK1071685A1 (zh)
HR (3) HRP20050886B1 (zh)
HU (2) HUE028247T2 (zh)
IL (3) IL170888A (zh)
IS (2) IS2682B (zh)
IT (1) ITMI20040682A1 (zh)
LU (1) LU91867I2 (zh)
MA (1) MA27729A1 (zh)
MX (1) MXPA05010860A (zh)
MY (1) MY141249A (zh)
NO (4) NO329332B1 (zh)
NZ (3) NZ592339A (zh)
PE (5) PE20090743A1 (zh)
PL (2) PL1613288T3 (zh)
PT (1) PT1613288E (zh)
RU (5) RU2358716C2 (zh)
SG (1) SG175449A1 (zh)
SI (2) SI1613288T1 (zh)
TN (1) TNSN05256A1 (zh)
TW (1) TWI332847B (zh)
WO (1) WO2004089341A1 (zh)
ZA (1) ZA200507394B (zh)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773307B8 (en) * 2004-07-30 2014-12-17 Novartis AG Compound formulations of 2-amino-1,3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
AU2006289100B2 (en) 2005-09-09 2010-07-22 Novartis Ag Treatment of autoimmune diseases
PL1948678T3 (pl) 2005-11-09 2013-09-30 Onyx Therapeutics Inc Związki do hamowania enzymów
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2041158B1 (en) 2006-06-19 2013-04-17 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
MX2009002993A (es) * 2006-09-26 2009-04-01 Novartis Ag Composiciones farmaceuticas que comprenden un modulador de s1p.
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
WO2008129846A1 (ja) * 2007-03-29 2008-10-30 Daiichi Sankyo Company, Limited 医薬組成物
PL2207791T5 (pl) 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
MY159358A (en) * 2007-10-12 2016-12-30 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
LT2278960T (lt) 2008-03-17 2017-02-10 Actelion Pharmaceuticals Ltd. S1p1 receptoriaus selektyvaus agonisto dozavimo režimas
MX2010014223A (es) 2008-06-20 2011-01-21 Novartis Ag Composiciones pediatricas para el tratamiento de esclerosis multiple.
CA2728436C (en) * 2008-06-20 2016-07-26 Merck Patent Gmbh Directly compressible and rapidly disintegrating tablet matrix
KR101651702B1 (ko) * 2008-09-04 2016-08-26 카아길, 인코포레이팃드 에리쓰리톨 정제
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
BRPI0921533A2 (pt) 2008-11-11 2016-01-12 Novartis Ag composto orgânicos
EP2356090B1 (en) * 2008-11-11 2017-07-05 Novartis AG Crystalline forms of fingolimod hcl
RU2464271C1 (ru) 2008-12-17 2012-10-20 Дайити Санкио Компани, Лимитед Способ получения производного диамина
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd INHIBITOR OF AN ACTIVE FACTOR OF BLOOD COAGULATION
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
JPWO2010147169A1 (ja) * 2009-06-18 2012-12-06 第一三共株式会社 溶出性の改善された医薬組成物
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
BR112012023654B1 (pt) 2010-03-19 2022-04-12 Daiichi Sankyo Company, Limited Método para produzir grânulos contendo agente anticoagulante e método para produzir uma composição farmacêutica contendo o dito agente
WO2011115066A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
EP2560619A2 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
KR101795096B1 (ko) 2010-07-02 2017-12-01 다이이찌 산쿄 가부시키가이샤 광학 활성 디아민 유도체의 염의 제조 방법
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMODE POLYMORPHS AND METHODS THEREOF
LT2661261T (lt) 2011-01-07 2019-10-25 Novartis Ag Imunosupresantų kompozicijos
ES2662373T3 (es) 2011-01-19 2018-04-06 Pathologica, Llc. Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
JPWO2013022059A1 (ja) 2011-08-10 2015-03-05 第一三共株式会社 ジアミン誘導体含有医薬組成物
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP6370804B2 (ja) 2013-01-08 2018-08-08 パソロジカ エルエルシー 脱髄疾患の治療のための方法および組成物
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
JP6294872B2 (ja) * 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
MX370184B (es) * 2013-05-13 2019-12-04 Synthon Bv Composición farmacéutica que comprende fingolimod.
CA2920758A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
PT812588E (pt) 1995-12-28 2005-01-31 Mitsubishi Pharma Corp Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
RU2188004C2 (ru) * 1997-02-27 2002-08-27 Велфайд Корпорейшн Фармацевтическая композиция
CA2286315C (en) * 1997-04-04 2007-03-06 Yoshitomi Pharmaceutical Industries Ltd. 2-aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
KR100812578B1 (ko) 2000-07-13 2008-03-13 상꾜 가부시키가이샤 아미노알코올 유도체
CA2421893A1 (en) * 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
ES2254675T3 (es) 2001-03-26 2006-06-16 Novartis Ag Derivados del 2-amino-propanol.
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
DE60223699T2 (de) 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
EP1772145B1 (en) * 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect

Also Published As

Publication number Publication date
JP2004307506A (ja) 2004-11-04
EP2319502A1 (en) 2011-05-11
RU2475237C2 (ru) 2013-02-20
CY2011013I2 (el) 2014-04-09
SI2316431T1 (sl) 2016-04-29
US20090203798A1 (en) 2009-08-13
ES2320767T3 (es) 2009-05-28
CN1767819B (zh) 2010-07-28
BRPI0409250B1 (pt) 2017-07-11
IL197578A0 (en) 2011-07-31
CA2707750A1 (en) 2004-10-21
AT501681B1 (de) 2012-04-15
US20060275357A1 (en) 2006-12-07
DE122011100047I1 (de) 2011-12-15
EP1613288A1 (en) 2006-01-11
AR043987A1 (es) 2005-08-17
HRP20100601B1 (hr) 2016-12-02
IL170888A (en) 2010-06-16
ES2556947T3 (es) 2016-01-21
HRP20050886B1 (en) 2011-01-31
HUE028247T2 (en) 2016-12-28
NO20131287L (no) 2006-01-09
NZ592339A (en) 2012-09-28
RU2005134173A (ru) 2006-09-10
IS8885A (is) 2010-02-25
RU2358716C2 (ru) 2009-06-20
PE20131352A1 (es) 2013-11-14
RU2009105403A (ru) 2010-08-27
FR2854073A1 (fr) 2004-10-29
SG175449A1 (en) 2011-11-28
US8324283B2 (en) 2012-12-04
IE20040246A1 (en) 2004-12-15
NZ542622A (en) 2009-01-31
JP2011006461A (ja) 2011-01-13
EP2008650A2 (en) 2008-12-31
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
CY2011013I1 (el) 2014-04-09
US20220031609A1 (en) 2022-02-03
FR2854073B1 (fr) 2008-03-14
SI1613288T1 (sl) 2009-04-30
CL2004000745A1 (es) 2005-02-11
AR078781A2 (es) 2011-11-30
LU91867I2 (fr) 2011-11-08
ITMI20040682A1 (it) 2004-07-06
US20140255497A1 (en) 2014-09-11
TNSN05256A1 (en) 2007-07-10
EP2316431B1 (en) 2015-09-30
US20080311188A1 (en) 2008-12-18
HK1091114A1 (en) 2007-01-12
NO334116B1 (no) 2013-12-16
AT501681A1 (de) 2006-10-15
CN1767819A (zh) 2006-05-03
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
CN101797241B (zh) 2013-03-27
BRPI0409250B8 (pt) 2022-01-18
CY1110260T1 (el) 2014-04-09
GR20040100121A (el) 2004-12-17
RU2010147000A (ru) 2012-08-10
US20200237690A1 (en) 2020-07-30
DE202004021680U1 (de) 2010-04-22
NZ586280A (en) 2011-12-22
HUS1100016I1 (hu) 2016-08-29
HRP20100601A2 (hr) 2011-03-31
EP2769713A1 (en) 2014-08-27
GR1005052B (el) 2005-11-30
CA2521325A1 (en) 2004-10-21
BRPI0409250A (pt) 2006-03-28
US20140011885A1 (en) 2014-01-09
MY141249A (en) 2010-03-31
TWI332847B (en) 2010-11-11
NO329332B1 (no) 2010-09-27
ATE414508T1 (de) 2008-12-15
PL1613288T3 (pl) 2009-07-31
IL242037A0 (en) 2015-11-30
WO2004089341A1 (en) 2004-10-21
US20130108675A1 (en) 2013-05-02
US20110105620A1 (en) 2011-05-05
CN101797241A (zh) 2010-08-11
AU2004228929A1 (en) 2004-10-21
PE20090743A1 (es) 2009-07-17
EP1613288B1 (en) 2008-11-19
GB0407819D0 (en) 2004-05-12
HRP20100600A2 (hr) 2011-03-31
HRP20050886A2 (en) 2006-11-30
KR20110005320A (ko) 2011-01-17
MXPA05010860A (es) 2006-05-25
RU2012148593A (ru) 2014-05-20
NO335120B1 (no) 2014-09-22
DE602004017847D1 (de) 2009-01-02
FR11C0036I2 (fr) 2023-12-29
ZA200507394B (en) 2007-03-28
DK2316431T3 (en) 2016-01-11
GB2400318B (en) 2005-08-10
LU91867I9 (zh) 2019-01-03
AR078782A2 (es) 2011-11-30
MA27729A1 (fr) 2006-01-02
JP2013177404A (ja) 2013-09-09
RU2010146697A (ru) 2012-05-27
AU2004228929B2 (en) 2008-02-07
NO20100250L (no) 2006-01-09
PE20050396A1 (es) 2005-07-05
BE2011C030I2 (zh) 2023-03-07
TW200503784A (en) 2005-02-01
KR20050121712A (ko) 2005-12-27
IS2682B (is) 2010-10-15
CA2521325C (en) 2010-09-14
NO2011016I2 (no) 2012-08-27
ES2228282A1 (es) 2005-04-01
PE20150676A1 (es) 2015-05-17
DE102004016947A1 (de) 2004-10-21
NO20055231D0 (no) 2005-11-07
DK1613288T3 (da) 2009-03-23
JP5543298B2 (ja) 2014-07-09
IS8114A (is) 2005-11-01
EP2008650A3 (en) 2011-04-27
US20170290787A1 (en) 2017-10-12
KR20120101148A (ko) 2012-09-12
GB2400318A (en) 2004-10-13
ECSP056090A (es) 2006-03-01
JP5495467B2 (ja) 2014-05-21
PE20130200A1 (es) 2013-03-09
KR101367574B1 (ko) 2014-02-25
IL197578A (en) 2015-10-29
PT1613288E (pt) 2009-02-25
CY1117071T1 (el) 2017-04-05
US20190175527A1 (en) 2019-06-13
ES2228282B1 (es) 2006-02-16
FR11C0036I1 (fr) 2011-10-14
NO2011016I1 (no) 2011-09-19
AT504853A2 (de) 2008-08-15
RU2475236C2 (ru) 2013-02-20
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25

Similar Documents

Publication Publication Date Title
HK1155647A1 (zh) 含有 受體激動劑及糖醇的固體藥物組合物
PT2277521E (pt) Formulações orais de agonistas de opióides resistentes a adulteração
IL169902A0 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
HK1107768A1 (en) Solid drug for oral use
EP1701691A4 (en) METHODS AND COMPOSITIONS FOR ORAL HYGIENE
ZA200606174B (en) Multiparticulate formulations for oral delivery
HK1107012A1 (zh) 含有多巴胺受體激動劑類藥物的長效緩釋製劑及其製備工藝
ZA200508733B (en) Muscarinic M1 receptor agonists for pain management
IL177826A0 (en) Oral matrix formulations comprising licarbazepine
EP1757273A4 (en) PREPARATION FOR ORAL ADMINISTRATION
GB2391809B (en) Pharmaceutical composition comprising honey
IL161997A (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
IL178296A0 (en) Pharmaceutical compositions containing a gaba?? receptor agonist
EP1811967A4 (en) METHOD AND FORMULATIONS FOR PREPARING PHARMACEUTICAL COMPOSITIONS WITH BUPROPION
GB0325383D0 (en) Oral formulations
EP1755477A4 (en) MOUTH HYGIENE COMPOSITIONS AND METHOD OF USE THEREOF
GB2403407B (en) Palatable oral anthelmintic composition
EP1614417A4 (en) SOLID PREPARATION FOR ORAL USE
PL377147A1 (pl) Doustna kompozycja
AU2003280065A1 (en) Bupropion hydrochloride solid dosage forms
PL373776A1 (en) Oral pharmaceutical compound
GB0406393D0 (en) Oral composition
GB0406392D0 (en) Oral composition
GB0413138D0 (en) Preparation for oral administration
AU2004900654A0 (en) Oral Hygiene Device

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190409